Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Finished Goods (2021 - 2024)

Apellis Pharmaceuticals (APLS) has 4 years of Finished Goods data on record, last reported at $13.0 million in Q1 2024.

  • For Q1 2024, Finished Goods rose 325.22% year-over-year to $13.0 million; the TTM value through Mar 2024 reached $13.0 million, up 325.22%, while the annual FY2023 figure was $30.7 million, 1639.18% up from the prior year.
  • Finished Goods reached $13.0 million in Q1 2024 per APLS's latest filing, down from $30.7 million in the prior quarter.
  • Across five years, Finished Goods topped out at $30.7 million in Q4 2023 and bottomed at $479000.0 in Q4 2021.
  • Average Finished Goods over 4 years is $9.4 million, with a median of $2.4 million recorded in 2022.
  • Peak YoY movement for Finished Goods: soared 268.68% in 2022, then soared 2909.64% in 2023.
  • A 4-year view of Finished Goods shows it stood at $479000.0 in 2021, then skyrocketed by 268.68% to $1.8 million in 2022, then soared by 1639.18% to $30.7 million in 2023, then plummeted by 57.57% to $13.0 million in 2024.
  • Per Business Quant database, its latest 3 readings for Finished Goods were $13.0 million in Q1 2024, $30.7 million in Q4 2023, and $20.3 million in Q3 2023.